Drospirenone/ethinyl estradiol versus rosiglitazone treatment in overweight adolescents with polycystic ovary syndrome: comparison of metabolic, hormonal, and cardiovascular risk factors.
about
Early Biomarkers of Subclinical Atherosclerosis in Obese Adolescent Girls with Polycystic Ovary SyndromeDistinguishing characteristics of metabolically healthy versus metabolically unhealthy obese adolescent girls with polycystic ovary syndromePolycystic ovary syndrome and nonalcoholic fatty liver in obese adolescents: association with metabolic risk profile.PCOS in adolescence and type 2 diabetes.Cardiovascular risk factors and events in women with androgen excess.Optimal management of polycystic ovary syndrome in adolescence.The Shape of the Glucose Response Curve During an Oral Glucose Tolerance Test Heralds Biomarkers of Type 2 Diabetes Risk in Obese Youth.Contraception quandaries: oral contraceptive decisions in the pediatric endocrinology office.Ethinyl estradiol-drospirenone vs ethinyl estradiol-drospirenone plus metformin in the treatment of lean women with polycystic ovary syndrome.Impaired Lipolysis, Diminished Fat Oxidation and Metabolic Inflexibility in Obese Girls with Polycystic Ovary Syndrome.Anti-Müllerian Hormone in Obese Adolescent Girls With Polycystic Ovary Syndrome.Increased Adrenal Androgens in Overweight Peripubertal Girls.Hyperinsulinaemic androgen excess in adolescent girls
P2860
Q36421176-AD03EA17-5296-48D6-9D57-012D85B1584DQ36971110-AB96F9D0-9BE7-4D1A-ACC4-8C8DD12FE2E5Q37351152-07BDD270-4308-48E9-856D-23F7BCB2E404Q38268267-0AA06E07-50D2-49D6-93C7-E97518418B3DQ38272385-2B3CCDA2-AC19-4B2E-AB9D-BB6412D51B1FQ38535106-612B5DD7-5C22-4EF4-8E7E-50121E59A1F6Q41781089-2688743F-3AA7-4885-AE84-C6B0245D09A4Q43046426-1D1A04F4-5ECF-442E-9586-43D53F03F596Q43871392-E3DDEA5B-FCDC-4644-8D4C-7DAFB8FAC5A7Q47686459-89F120FF-58A4-4F32-96D3-43D263002E0DQ53756802-4126F595-C9F4-49A5-935E-2D7C28CC4B6AQ55353715-2405ADEE-2BA3-42B9-B29A-9ABCAFFA2BB2Q58811102-C1D6322B-F031-49D7-B922-B51E9A42D72D
P2860
Drospirenone/ethinyl estradiol versus rosiglitazone treatment in overweight adolescents with polycystic ovary syndrome: comparison of metabolic, hormonal, and cardiovascular risk factors.
description
2011 nî lūn-bûn
@nan
2011 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Drospirenone/ethinyl estradiol ...... d cardiovascular risk factors.
@ast
Drospirenone/ethinyl estradiol ...... d cardiovascular risk factors.
@en
type
label
Drospirenone/ethinyl estradiol ...... d cardiovascular risk factors.
@ast
Drospirenone/ethinyl estradiol ...... d cardiovascular risk factors.
@en
prefLabel
Drospirenone/ethinyl estradiol ...... d cardiovascular risk factors.
@ast
Drospirenone/ethinyl estradiol ...... d cardiovascular risk factors.
@en
P2093
P2860
P921
P356
P1476
Drospirenone/ethinyl estradiol ...... nd cardiovascular risk factors
@en
P2093
Hala Tfayli
Julia Warren Ulnach
Kim Sutton-Tyrrell
Silva Arslanian
P2860
P304
P356
10.1210/JC.2010-2547
P407
P50
P577
2011-02-16T00:00:00Z